undamentalytics Newsletter
Sign in

Addus Homecare Corp (ADUS) stock

Add to watchlist

Add holding +

NASDAQ: ADUS Nasdaq Health Care Services Next results ~November 3, 2026

C+ Fundamentals grade

Addus Homecare Corp is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$210

Cash-flow model

Base case. Range ~$160–$270 across our lower- and higher-growth cases (9.9%–19.9% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 66% above it.

Price used: $125.75, November 2, 2026

Addus Homecare Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 11 selling0 purchases and 36 sales by directors and officers, last 12 monthsInsider trades
  • Funds158 adding, 129 cuttingOf 43 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Addus Homecare files

Where Addus Homecare stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $1.48bn, up 15.9% on a year earlier, slower than the 19.6% growth a quarter earlier. Free-cash-flow margin rose to 10.5% from 7.4% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 6 of our 6 financial-health checks. Our cash-flow model value is $211 a share, against a share price of $121. At that price, our model says the market is pricing in about 2.8% a year of cash-flow growth for five years, slower than the 11.3% a year revenue growth it has delivered.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Addus Homecare Corp's trailing-twelve-month revenue grew 15.9% year on year, with a free-cash-flow margin of 10.5%. Where it stands out: long-term debt as % of assets of 4.2% ranks 5 of 31 health care services companies we cover. Where it lags: change in growth rate of -3.7pp ranks 36 of 41 health care services companies we cover.

Our discounted-cash-flow model values the business at ~$210 per share in the base case (~$160–$270 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 65.3% while net income grew 26.9%: a 38pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $125.75 is 66% below our value per share of $210.
  • Fast growth. Revenue grew 15.9% over the last 12 months, against a median of 7.3% for health care services companies we cover.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Growth easing. The growth rate is 3.7 points lower than a quarter earlier.
  • Below peers: change in growth rate. Change in growth rate of -3.7pp ranks 36 of 41 health care services companies we cover (median +1.1pp).

Latest results: FY2026 Q2

Filed August 4, 2026
Earnings per share
$1.73 against an average estimate of $1.70: beat by 1.9%
Revenue
$377m, up 8.0% on a year earlier
Share reaction
-1.6% in the first session after the results on August 3, 2026, against +3.3% for the S&P 500
Next report
November 3, 2026; average EPS estimate $1.79

Addus Homecare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.2%
  • 1 week+3.8%
  • 1 month+13.0%
  • This year+17.1%
  • 1 year+7.6%
  • 5 years+27.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.5B
Operating margin
10.0%
Net margin
7.1%
EPS (TTM, diluted)
$5.70

Growth

Revenue growth
+15.9%
Change in growth rate
−3.7 pts
Share count change
+0.8%

Cash

Free cash flow (TTM)
$155M
FCF margin
10.5%
Stock pay % of revenue
1.2%

Earnings

Last results
August 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Leadership
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Addus Homecare Corp valuation models and calculator

What the price is pricing in

The share price implies about 3.7% a year of cash-flow growth for five years.That is slower than the 11.3% a year revenue growth Addus Homecare has delivered.

  • Priced in3.7%
  • Last 12 months15.9%
  • 3 years a year13.9%
  • 5 years a year11.3%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($126.03, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$210
Price used
$126.03close November 3, 2026
Implied change
▲ +66%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Addus Homecare Corp's free cash flow after stock-based pay with after-tax interest added back ($126M, FY2026 Q2 TTM), growing 8.6% and 11.4% in the next two years (forecasts, guidance and its record), then back to 14.9% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$160–~$270 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Addus Homecare Corp's free cash flow after stock-based pay ( $126M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Addus Homecare Corp as an operating company, with every model that fits that kind of business. Cost of equity 8.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.7 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$210 ~$160–$270 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$140 ~$110–$210 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$67 ~$42–$110 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$68 ~$57–$85 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$140 ~$67–$210 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Addus Homecare Corp with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −24%
  • Revenue growth 5 points higher ▲ +31%
  • Free-cash-flow margin 1 point lower ▼ −9%
  • Last year's free-cash-flow margin change, if it persists ▲ +39%
  • Discount rate 1 point higher ▼ −16%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $100$135$181$242$321$424
8.5% $77$102$135$179$236$308
10% $63$82$108$141$185$240

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$35.05$34.80$67.88$97.22$117.09$93.51$99.49$92.85$125.35$107.39$125.75
Market value$398m$404m$841m$1.4bn$1.9bn$1.5bn$1.6bn$1.5bn$2.2bn$2.0bn$2.3bn
+ Net debt (− = net cash)$17m−$11m−$53m−$52m$50m$52m$52m$59m$120m$0$0
Enterprise value$415m$394m$787m$1.3bn$1.9bn$1.6bn$1.7bn$1.6bn$2.3bn$2.0bn$2.3bn
Multiples
Price / sales 1.0x0.9x1.6x2.1x2.4x1.7x1.7x1.4x1.9x1.4x1.6x
Price / earnings 32.7x33.8x51.2x54.9x56.4x33.3x35.0x24.2x29.6x20.6x22.1x
Price / free cash flow —8.2x30.2x187.2x18.2x43.1x16.6x14.7x19.7x19.0x15.0x
EV / EBITDA 18.7x12.3x25.0x29.4x33.9x19.3x20.1x15.0x19.8x12.7x14.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

47 /100

Moderate moat

How hard Addus Homecare's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 5 / 20

    Net income has been a median 4.7% of total assets over 10 years.

  • Pricing power 11 / 20

    Gross margin has been a median 31.5%, moving by 2.2 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median 7.4%; its worst year was 4.4%.

  • Cash conversion 15 / 20

    Free cash flow was positive in 9 of 9 years, at a median 8.9% of revenue.

  • Discipline 12 / 20

    The diluted share count rose 15.3% over five years; stock-based pay has been a median 1.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (52 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $389m and EPS of $1.79 (range $1.75 to $1.86) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $7.05 +13% $1.5bn +7%
Next $7.52 +7% $1.6bn +5%

Next year's EPS estimate has moved +0.4% in 90 days, across 13 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.7% on 90 days ago. In the last 30 days, 2 analysts raised Addus Homecare Corp's forecast and 0 cut it.

Consensus EPS forecast Addus Homecare Corp, last 90 days
$7.00 $7.20 $7.40 $7.60 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $7.00 Current fiscal year, 60 days ago: $7.04 Current fiscal year, 30 days ago: $7.05 Current fiscal year, 7 days ago: $7.05 Current fiscal year, Now: $7.05 $7.05 Next fiscal year, 90 days ago: $7.48 Next fiscal year, 60 days ago: $7.52 Next fiscal year, 30 days ago: $7.51 Next fiscal year, 7 days ago: $7.52 Next fiscal year, Now: $7.52 $7.52

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $7.00$7.48
60 days ago $7.04$7.52
30 days ago $7.05$7.51
7 days ago $7.05$7.52
Now $7.05$7.52

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $1.70 $1.73 +1.9%
Mar 2026 $1.54 $1.62 +4.9%
Dec 2025 $1.72 $1.77 +2.6%
Sept 2025 $1.53 $1.56 +1.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 3, 2026

No numeric guidance in Addus Homecare Corp's latest earnings release (filed August 3, 2026). Some companies give their outlook only on the earnings call.

How our valuation uses these forecasts

Our cash-flow model grows Addus Homecare Corp's revenue by +8.6% next year and +11.4% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+5.7%, weight 69%) and the company's own record (+14.9%, weight 31%) . How the weights are set.

Analyst recommendations

14 analysts, Nov 2026
Buy1179%
Hold214%
Sell17%

Monthly trend

  1. Nov 2026382114
  2. Oct 2026382114
  3. Sep 2026391114

Counts of recommendations published by analysts covering Addus Homecare Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.0%
of tradable shares
Days to cover
3.57
at average volume
Short interest, 1 month
−12%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
2.8%
of shares
Employees
5,982
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +7.6%

$116.89 on October 31, 2025 to $125.75

ThenNowEffect
Revenue (last 12 months) $1.3bn $1.5bn +15.9%
Net margin 6.5% 7.1% +9.5%
P/E multiple 25.8x 22.1x −14.6%
Share count 18m 18m −0.8%

Biggest factor: p/e multiple.

Last 3 years +48.5%

$84.67 on November 3, 2023 to $125.75

ThenNowEffect
Revenue (last 12 months) $999m $1.5bn +47.8%
Net margin 5.4% 7.1% +32.4%
P/E multiple 25.6x 22.1x −13.8%
Share count 16m 18m −11.9%

Biggest factor: revenue.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ADUS−20%+6%−7%+35%−14%+17%
Industry peers (median)−1%−28%+8%−6%−6%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ADUS33%50%50%67%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ADUS−43%−25%−31%−12%−34%−25%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 53% from February 14, 2020 to March 17, 2020. Getting back needed a 115% gain, reached on October 22, 2020, 219 days after the low.

Price behaviour

52-week range
$88.49 – $125.75
From 52-week high
0.0%
vs 50-day average
+7.4%
vs 200-day average
+18.1%
Volatility (1 year)
29%
Beta vs S&P 500
0.13

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±5.0%
After a week
8 up, 4 down
typical move ±6.0%
After a month
7 up, 5 down
typical move ±8.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 3, 2026 −1.6% +3.3% +3.3% −0.8%
May 4, 2026 −1.1% +0.4% −1.8% −11.1%
February 23, 2026 −8.9% −0.3% −8.9% −14.0%
November 3, 2025 −4.0% −1.0% −3.5% +0.9%
August 4, 2025 +11.1% +1.0% +6.7% +7.8%
May 5, 2025 +3.4% −1.4% +5.3% +6.7%
February 24, 2025 −10.7% −1.0% −13.0% −13.0%
November 4, 2024 −1.7% +1.0% +1.3% −2.1%
August 5, 2024 +3.5% −2.0% +4.3% +8.5%
May 6, 2024 +6.5% +1.1% +12.6% +16.8%
February 26, 2024 +3.4% −0.2% +7.5% +15.1%
October 30, 2023 −3.7% +1.8% +3.5% +7.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Addus Homecare Corp’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade C+ (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Addus Homecare Corp in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Addus Homecare Corp
$1B $1.2B $1.4B $1.6B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1B Revenue (TTM), FY23 Q4: $1.1B Revenue (TTM), FY24 Q1: $1.1B Revenue (TTM), FY24 Q2: $1.1B Revenue (TTM), FY24 Q3: $1.1B Revenue (TTM), FY24 Q4: $1.2B Revenue (TTM), FY25 Q1: $1.2B Revenue (TTM), FY25 Q2: $1.3B Revenue (TTM), FY25 Q3: $1.3B Revenue (TTM), FY25 Q4: $1.4B Revenue (TTM), FY26 Q1: $1.4B Revenue (TTM), FY26 Q2: $1.5B $1.5B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1B
FY23 Q4 $1.1B
FY24 Q1 $1.1B
FY24 Q2 $1.1B
FY24 Q3 $1.1B
FY24 Q4 $1.2B
FY25 Q1 $1.2B
FY25 Q2 $1.3B
FY25 Q3 $1.3B
FY25 Q4 $1.4B
FY26 Q1 $1.4B
FY26 Q2 $1.5B
Revenue growth, TTM YoY Addus Homecare Corp
5% 10% 15% 20% 25% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 10.8% Revenue growth, TTM YoY, FY23 Q4: 11.3% Revenue growth, TTM YoY, FY24 Q1: 11.4% Revenue growth, TTM YoY, FY24 Q2: 11.6% Revenue growth, TTM YoY, FY24 Q3: 10.1% Revenue growth, TTM YoY, FY24 Q4: 9.1% Revenue growth, TTM YoY, FY25 Q1: 11.4% Revenue growth, TTM YoY, FY25 Q2: 14.3% Revenue growth, TTM YoY, FY25 Q3: 18.8% Revenue growth, TTM YoY, FY25 Q4: 23.2% Revenue growth, TTM YoY, FY26 Q1: 19.6% Revenue growth, TTM YoY, FY26 Q2: 15.9% 15.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 10.8%
FY23 Q4 11.3%
FY24 Q1 11.4%
FY24 Q2 11.6%
FY24 Q3 10.1%
FY24 Q4 9.1%
FY25 Q1 11.4%
FY25 Q2 14.3%
FY25 Q3 18.8%
FY25 Q4 23.2%
FY26 Q1 19.6%
FY26 Q2 15.9%
Operating margin (TTM) Addus Homecare Corp
8% 8.5% 9% 9.5% 10% 10.5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 8.1% Operating margin (TTM), FY23 Q4: 8.6% Operating margin (TTM), FY24 Q1: 8.8% Operating margin (TTM), FY24 Q2: 9.0% Operating margin (TTM), FY24 Q3: 9.2% Operating margin (TTM), FY24 Q4: 8.9% Operating margin (TTM), FY25 Q1: 9.0% Operating margin (TTM), FY25 Q2: 9.1% Operating margin (TTM), FY25 Q3: 9.2% Operating margin (TTM), FY25 Q4: 9.7% Operating margin (TTM), FY26 Q1: 9.8% Operating margin (TTM), FY26 Q2: 10.0% 10.0%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 8.1%
FY23 Q4 8.6%
FY24 Q1 8.8%
FY24 Q2 9.0%
FY24 Q3 9.2%
FY24 Q4 8.9%
FY25 Q1 9.0%
FY25 Q2 9.1%
FY25 Q3 9.2%
FY25 Q4 9.7%
FY26 Q1 9.8%
FY26 Q2 10.0%
FCF margin (TTM) Addus Homecare Corp
6% 8% 10% 12% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 9.4% FCF margin (TTM), FY23 Q4: 9.7% FCF margin (TTM), FY24 Q1: 11.2% FCF margin (TTM), FY24 Q2: 8.9% FCF margin (TTM), FY24 Q3: 11.1% FCF margin (TTM), FY24 Q4: 9.6% FCF margin (TTM), FY25 Q1: 7.4% FCF margin (TTM), FY25 Q2: 7.4% FCF margin (TTM), FY25 Q3: 7.2% FCF margin (TTM), FY25 Q4: 7.3% FCF margin (TTM), FY26 Q1: 9.5% FCF margin (TTM), FY26 Q2: 10.5% 10.5%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 9.4%
FY23 Q4 9.7%
FY24 Q1 11.2%
FY24 Q2 8.9%
FY24 Q3 11.1%
FY24 Q4 9.6%
FY25 Q1 7.4%
FY25 Q2 7.4%
FY25 Q3 7.2%
FY25 Q4 7.3%
FY26 Q1 9.5%
FY26 Q2 10.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Addus Homecare took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $1.4B
  2. Cost of revenue $961M · 67.5%
  3. Gross profit $462M · 32.5%
  4. Selling, general and admin $307M · 21.6%
  5. Other operating costs $16.4M · 1.2%
  6. Operating income $139M · 9.7%
  7. Income tax $31.5M · 2.2%
  8. Interest and other $11.2M · 0.8%
  9. Net income $95.9M · 6.7%

Shares of revenue. Source: Addus Homecare's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 401 426 517 649 765 864 951 1,059 1,155 1,423 1,476
Gross profit 106 116 137 179 226 270 300 340 375 462 478
EBITDA 22 32 31 45 57 80 83 105 116 155 165
Operating income 15 25 23 35 45 66 69 91 103 139 148
Net income 12 12 16 25 33 45 46 63 74 96 105
Diluted EPS $1.07 $1.03 $1.33 $1.77 $2.08 $2.81 $2.84 $3.83 $4.23 $5.22 $5.70
Growth (year on year)
Revenue — +6.3% +21.3% +25.6% +17.9% +13.0% +10.0% +11.3% +9.1% +23.2% +15.9%
EBITDA — +44.3% −1.4% +44.0% +24.8% +42.2% +2.9% +26.9% +10.6% +33.4% +26.1%
Operating income — +63.2% −9.6% +52.2% +28.1% +48.1% +4.2% +32.3% +12.9% +35.0% +27.5%
Net income — −1.7% +37.5% +53.6% +31.3% +36.2% +2.0% +35.8% +17.7% +30.3% +26.9%
Diluted EPS — −3.7% +29.1% +33.1% +17.5% +35.1% +1.1% +34.9% +10.4% +23.4% +25.9%
Margins
Gross margin 26.5% 27.2% 26.5% 27.6% 29.6% 31.2% 31.5% 32.1% 32.5% 32.5% 32.4%
EBITDA margin 5.5% 7.5% 6.1% 7.0% 7.4% 9.3% 8.7% 9.9% 10.1% 10.9% 11.2%
Operating margin 3.9% 5.9% 4.4% 5.4% 5.8% 7.6% 7.2% 8.6% 8.9% 9.7% 10.0%
Net margin 3.0% 2.8% 3.2% 3.9% 4.3% 5.2% 4.8% 5.9% 6.4% 6.7% 7.1%
Free-cash-flow margin −0.6% 11.5% 5.4% 1.1% 13.4% 4.0% 10.2% 9.7% 9.6% 7.3% 10.5%
Cash flow
Cash from operations −1 53 33 12 109 39 105 112 116 112 162
Capital spending 2 4 5 5 7 5 8 9 6 8 8
Free cash flow −2 49 28 7 103 35 97 103 110 104 155
Stock-based pay 1 3 4 6 6 9 11 10 11 16 18
Free cash flow after stock pay −4 47 24 2 97 25 86 92 99 87 137
Balance sheet
Cash 8 54 70 112 145 169 80 65 99 — —
Total debt 25 43 17 60 195 221 132 124 218 121 62
Net debt (negative = net cash) 17 −11 −53 −52 50 52 52 59 120 — —
Diluted shares 11m 12m 12m 14m 16m 16m 16m 16m 17m 18m 18m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 6 checks passed · June 30, 2026
What it owns · $1.5bn
Short-term assets $284mLonger-term assets $1.2bn
What it owes, and who funded it · $1.5bn
Short-term liabilities $168mLonger-term liabilities $140mShareholders' equity $1.1bn
  • Short-term assets cover short-term liabilities $284m of assets due within a year against $168m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $284m short-term assets against $140m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Debt is 5% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 38% to 5% over five years.
  • A year's operating cash flow covers at least 20% of debt $162m of operating cash flow against $62m of debt.
  • Operating profit covers interest at least five times over Operating income of $148m against $10m of interest.

From Addus Homecare Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+0.8%
year over year
Days sales outstanding
36 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated ADUS PIII HQY PGNY GH PNTG Median
Revenue, last 12 months $1.5bn $1.5bn $1.4bn $1.3bn $1.2bn $1.1bn $1.2bn
Revenue growth, last 12 months 15.9% 2.8% 7.3% 5.5% 42.7% 37.9% 7.3%
Revenue growth, 3-year average 13.9% 9.7% 13.2% 11.0% 32.4% 30.0% 11.3%
Revenue growth, latest quarter 8.0% 8.6% 7.6% 5.3% 44.3% 35.8% 8.5%
Gross margin 32.4% — 71.2% 24.6% 65.0% — 27.9%
Operating margin 10.0% −9.9% 25.8% 8.6% −39.7% 5.6% 2.3%
Operating margin, 3-year average 9.4% −14.7% 19.9% 7.0% −58.3% 5.5% 2.3%
Net margin 7.1% −6.6% 17.4% 6.0% −38.3% 2.9% 1.2%
Cash from operations / revenue 11.0% −8.7% 36.0% 15.4% −15.7% 4.8% 6.1%
Free-cash-flow margin 10.5% −8.7% 35.8% 13.6% −20.3% 3.1% 5.1%
Free-cash-flow margin, 3-year average 8.9% −7.1% 30.8% 14.7% −33.2% 3.5% 3.6%
Stock pay / revenue 1.2% 0.3% 6.0% 8.2% 16.2% 0.9% 1.1%
Change in share count 0.8% 40.0% −3.3% −4.2% 4.6% 3.6% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 15.9% 7.3% 15 of 41
Change in growth rate Growth -3.7pp +1.1pp 36 of 41
Gross margin Profitability 32.4% 29.0% 12 of 27
Operating margin Profitability 10.0% 2.6% 10 of 40
Net margin Profitability 7.1% 1.2% 8 of 41
Free-cash-flow margin Cash generation 10.5% 5.1% 10 of 40
Stock pay as % of revenue Cash generation 1.2% 0.9% 22 of 35
Long-term debt as % of assets Balance sheet 4.2% 27.7% 5 of 31
Change in share count Balance sheet 0.8% 0.4% 21 of 39
Days sales outstanding Balance sheet 36 days 39 days 14 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Personal Care $1.1B 76.6% ▲ 27.2%
Hospice $263M 18.5% ▲ 15.1%
Home Health $70.8M 5.0% ▲ 1.4%

From Addus Homecare Corp's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2B
Institutions reporting
300
Shares held vs prior quarter
▲ 1.0%
Positions opened / closed
39 / 36

Top buyers and sellers, Q2 2026: 158 institutions bought and 129 sold ; the biggest buyer was Blackrock, Inc (+335K shares) and the biggest seller Voya Investment Management LLC (−255K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $344M 3.4M 17.6% ▲ 10.8%
Capital Research Global Investors $140M 1.4M 7.2% ▼ 9.5%
Dimensional Fund Advisors LP $83.9M 835K 4.3% ▲ 12.2%
Vanguard Capital Management LLC $79.3M 789K 4.1% ▲ 0.6%
State Street Corp $78.1M 778K 4.0% ▲ 7.8%
Silvercrest Asset Management Group LLC $69.4M 691K 3.6% ▼ 5.2%
Wasatch Advisors LP $68.4M 681K 3.5% ▼ 21.5%
American Century Companies Inc $56.7M 565K 2.9% ▲ 77.4%
Geode Capital Management, LLC $51.8M 516K 2.7% ▲ 7.1%
Principal Financial Group Inc $41.3M 412K 2.1% ▼ 5.3%
Vanguard Portfolio Management LLC $39.2M 390K 2.0% ▲ 5.6%
Westwood Holdings Group Inc $39M 388K 2.0% ▲ 4.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Addus Homecare Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $5.3M 36 trades by 11 insiders · 57% under pre-set plans
Net ▼ $5.3M net selling
Insider Date Trade Shares Price Value
Dixon Heather Brianne President and Chief Operating June 22, 2026 Sell pre-set plan 288 $93.77 $27,006
Lopez Esteban Director May 21, 2026 Sell 250 $93.00 $23,250
Lopez Esteban Director May 19, 2026 Sell 250 $93.00 $23,250
Blessing Cliff Donald EVP, Chief Development Officer April 21, 2026 Sell pre-set plan 178 $93.61 $16,663
Raines Monica EVP, CCO and Quality Officer March 2, 2026 Sell pre-set plan 224 $102.15 $22,882
Allison R Dirk Chairman and CEO February 25, 2026 Sell pre-set plan 2,364 $105.36 $249,071
Poff Brian EVP, Chief Financial Officer February 25, 2026 Sell pre-set plan 820 $105.36 $86,395
Gaffney Sean EVP, Chief Legal Officer February 25, 2026 Sell pre-set plan 442 $105.36 $46,569
Anderson Darby EVP, Chief Govt Rel Officer February 25, 2026 Sell pre-set plan 396 $105.36 $41,723
Tucker David W. EVP, Chief Strategy Officer February 25, 2026 Sell pre-set plan 379 $105.36 $39,931
Wattenbarger Michael D. EVP, Chief Information Officer February 25, 2026 Sell pre-set plan 300 $105.36 $31,608
Blessing Cliff Donald EVP, Chief Development Officer February 25, 2026 Sell pre-set plan 177 $105.36 $18,649

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Addus Homecare Corp disclosed in the last 12 months; 1 earlier trade on record.

  • Donna Shalala(FL):Sale (full), $1,001 - $15,000, traded June 24, 2019, filed April 27, 2020

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 3, 2026
  • May 4, 2026
  • February 23, 2026
  • November 3, 2025
  • August 4, 2025
  • May 5, 2025

Recent SEC filings

Data status

When each part of this page on Addus Homecare Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Addus Homecare Corp in brief

What does Addus Homecare Corp do?
Addus Homecare Corp is a US-listed company in the health care services industry. Its financial year ends in December.
What is Addus Homecare Corp's stock ticker?
Addus Homecare Corp trades under the ticker ADUS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Addus Homecare Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Addus Homecare Corp reported revenue of $1.5B, 15.9% higher than a year earlier, according to its SEC filings.
What is Addus Homecare Corp's free cash flow?
Addus Homecare Corp's free-cash-flow margin is 10.5% of revenue over the trailing twelve months, ranking 10 of the 40 health care services companies we cover.
What is Addus Homecare Corp's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Addus Homecare Corp's free cash flow after stock-based pay gives ~$210 per share in the base case, and ~$160–$270 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Addus Homecare Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Capital Research Global Investors and Dimensional Fund Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Addus Homecare Corp's market cap?
On November 2, 2026, Addus Homecare Corp's market capitalisation was about $2.3B, with a price-to-earnings ratio of 22.1 and net debt of $0. Market figures come from third-party market data and may be delayed.
How much debt does Addus Homecare Corp have?
Addus Homecare Corp's debt-to-equity ratio is 5.4%, from its latest balance sheet (38.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are Addus Homecare Corp's competitors?
In our Health Care Services peer group, the companies closest to Addus Homecare Corp are P3 Health Partners Inc., Healthequity, Inc., Progyny, Inc., Guardant Health, Inc. and Pennant Group, Inc. The side-by-side comparison below sets their revenue, margins and growth against Addus Homecare Corp's.
Are insiders buying or selling Addus Homecare Corp stock?
Over the last 12 months, Addus Homecare Corp's directors and officers reported 0 open-market purchases and 36 sales on Form 4. The insider trading page charts every trade.
When is Addus Homecare Corp's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Addus Homecare Corp announces its own schedule.